Literature DB >> 23946419

Oncolytic virotherapy trials--letter.

Akseli Hemminki, Minna Oksanen, Maiju Merisalo-Soikkeli.   

Abstract

Mesh：

Year:  2013        PMID： 23946419     DOI： 10.1158/1078-0432.CCR-13-1471

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  12 in total

1.  Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.

Authors:  Kristian Taipale; Ilkka Liikanen; Juuso Juhila; Riku Turkki; Siri Tähtinen; Matti Kankainen; Lotta Vassilev; Ari Ristimäki; Anniina Koski; Anna Kanerva; Iulia Diaconu; Vincenzo Cerullo; Markus Vähä-Koskela; Minna Oksanen; Nina Linder; Timo Joensuu; Johan Lundin; Akseli Hemminki
Journal:  Mol Ther       Date:  2015-08-27       Impact factor: 11.454

2.  Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.

Authors:  Simona Bramante; Anniina Koski; Ilkka Liikanen; Lotta Vassilev; Minna Oksanen; Mikko Siurala; Raita Heiskanen; Tiina Hakonen; Timo Joensuu; Anna Kanerva; Sari Pesonen; Akseli Hemminki
Journal:  Oncoimmunology       Date:  2015-08-27       Impact factor: 8.110

Review 3.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

4.  T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.

Authors:  Kristian Taipale; Ilkka Liikanen; Juuso Juhila; Aila Karioja-Kallio; Minna Oksanen; Riku Turkki; Nina Linder; Johan Lundin; Ari Ristimäki; Anna Kanerva; Anniina Koski; Timo Joensuu; Markus Vähä-Koskela; Akseli Hemminki
Journal:  Mol Ther       Date:  2015-02-06       Impact factor: 11.454

5.  Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.

Authors:  Kristian Taipale; Ilkka Liikanen; Anniina Koski; Raita Heiskanen; Anna Kanerva; Otto Hemminki; Minna Oksanen; Susanna Grönberg-Vähä-Koskela; Kari Hemminki; Timo Joensuu; Akseli Hemminki
Journal:  Mol Ther       Date:  2016-04-04       Impact factor: 11.454

Review 6.  Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.

Authors:  William S M Wold; Karoly Toth
Journal:  Curr Gene Ther       Date:  2013-12       Impact factor: 4.391

7.  Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer.

Authors:  Tomoya Kato; Mikihito Nakamori; Shuichi Matsumura; Masaki Nakamura; Toshiyasu Ojima; Hiroshi Fukuhara; Yasushi Ino; Tomoki Todo; Hiroki Yamaue
Journal:  Oncol Lett       Date:  2021-04-23       Impact factor: 2.967

8.  Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.

Authors:  Otto Hemminki; Suvi Parviainen; Juuso Juhila; Riku Turkki; Nina Linder; Johan Lundin; Matti Kankainen; Ari Ristimäki; Anniina Koski; Ilkka Liikanen; Minna Oksanen; Dirk M Nettelbeck; Kalevi Kairemo; Kaarina Partanen; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Oncotarget       Date:  2015-02-28

9.  A novel oHSV-1 targeting telomerase reverse transcriptase-positive cancer cells via tumor-specific promoters regulating the expression of ICP4.

Authors:  Wen Zhang; Keli Ge; Qian Zhao; Xiufen Zhuang; Zhenling Deng; Lingling Liu; Jie Li; Yu Zhang; Ying Dong; Youhui Zhang; Shuren Zhang; Binlei Liu
Journal:  Oncotarget       Date:  2015-08-21

Review 10.  Trial Watch:: Oncolytic viruses for cancer therapy.

Authors:  Jonathan Pol; Norma Bloy; Florine Obrist; Alexander Eggermont; Jérôme Galon; Isabelle Cremer; Philippe Erbs; Jean-Marc Limacher; Xavier Preville; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-06-01       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.